$16.53 0.00 (0%)
2/10/2012 4:00 PM

Theravance, Inc. (NASDAQ:THRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.

Results 1 - 8 of 8

Recs

0
Member Avatar naughtyguy (91.78) Submitted: 8/19/2011 5:29:19 AM : Underperform Start Price: $17.32 THRX Score: +23.51

high market cap unjustified

Recs

1
Member Avatar zzlangerhans (99.26) Submitted: 8/18/2011 1:26:17 PM : Outperform Start Price: $17.70 THRX Score: -23.97

When I pooh poohed Theravance almost a year ago, televancin was the lead story and it wasn't a pretty one. Televancin sales and royalties for skin infections were dismal. Meanwhile the FDA had rejected televancin for pneumonia and the company didn't appear motivated to press the issue. At that time, Relovair seemed like a back story with a plot denouement that wouldn't take place until after a major broad market correction.

I seem to have been generally correct, but just barely. My market correction took longer than I anticipated, almost enough time for Relovair to launch out of the box. Enrollment is complete in the registrational trials of Relovair for asthma and for COPD, although topline data isn't anticipated until 2012. Meanwhile follow-on bronchodilators GSK73719 and GSK961081 continue enrollment in late stage trials. With every passing month Theravance looks more and more like the future pulmonary subdivision of GSK. Televancin royalties haven't improved, but in May it received a positive opinion for nosocomial pneumonia from CHMP. That means near certain EU approval for pneumonia within a few months.

You might be protesting that the markets haven't experienced a "correction" yet. I'd say they've corrected enough for me to take accuracy on my red thumb. There's a strong possibility they will correct more and put my new green thumb in a 20 point hole, at which point it is very likely that Theravance will go on the GBMB watchlist for the inevitable recovery.

Recs

0
Member Avatar withoutlimits (82.45) Submitted: 9/30/2010 7:50:58 PM : Underperform Start Price: $20.17 THRX Score: +34.89

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Recs

0
Member Avatar jsgant13 (96.11) Submitted: 9/13/2010 1:06:44 PM : Outperform Start Price: $15.11 THRX Score: -10.18

Klarman

Recs

0
Member Avatar Brian7992 (< 20) Submitted: 8/20/2009 7:40:30 AM : Outperform Start Price: $15.66 THRX Score: -29.31

Best Bio Bets

Recs

0
Member Avatar jmacn22 (86.65) Submitted: 2/5/2009 12:42:52 PM : Underperform Start Price: $16.26 THRX Score: +59.62

Should underperform

Recs

1
Member Avatar gklein711 (28.81) Submitted: 1/8/2008 1:53:53 PM : Outperform Start Price: $21.48 THRX Score: -21.77

Therevance appears to be a good company, but hit a rough spot. Should rebound from here.

Recs

0
Member Avatar star60629 (< 20) Submitted: 4/30/2007 8:58:01 PM : Underperform Start Price: $32.86 THRX Score: +45.40

Easiest way to find overvalued stocks go thru some biotechs.This one way overpriced Rev 20 Mil shares 60 mil. Insiders selling.Book value $1 . Muahhh look out below.My biotech shorts are outperforming. Get a basket of the worst ones and short.

Results 1 - 8 of 8

Featured Broker Partners


Advertisement